Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Haque T, Cadenas FL, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, Brunner AM, Chromik J, Morillo D, Patel MR, Falantes J, Leitch HA, Germing U, Preis M, Lenox L, Lauring J, Brown RJ, Kalota A, Mehta J, Pastore F, Gu J, Mistry P, Valcárcel D.
Haque T, et al. Among authors: morillo d.
Leuk Res. 2023 Nov;134:107390. doi: 10.1016/j.leukres.2023.107390. Epub 2023 Sep 20.
Leuk Res. 2023.
PMID: 37776843
Clinical Trial.